

# Ferring Pharmaceuticals Breakfast Meeting

Ferring Pharmaceuticals cordially invites you to a

## Breakfast Meeting

to be held in conjunction with the  
14th World Congress on Human Reproduction/Fertility Society of Australia Meeting

**Date:** Friday 2 December 2011

**Venue:** Melbourne Convention & Exhibition Centre  
1 Convention Centre Place  
South Wharf, Melbourne  
**(Meeting Room 210, Level 2, Stair 2)**

**Program:** 7.00am Arrive, coffee and registration

7.15am Presentation commences

**Guest Speaker: Dr Joan-Carles Arce, MD, PhD**  
Vice President, Clinical Development - Reproductive Health  
Ferring Pharmaceuticals, Copenhagen, Denmark

**Topic:**  
**MENOPUR - Evidence at Current Clinical Standards**

8.00am Questions and Discussion

8.20am Close & depart

**Note:** Breakfast will be served during the Presentation

### MENOPUR - Evidence at Current Clinical Standards

Gonadotrophin preparations containing FSH and LH activity provide a differentiated pharmacokinetic/ pharmacodynamic profile compared with those containing only FSH activity including differences in follicular development, ovarian response, embryo quality, endocrine profile and endometrial profile.

The impact of different gonadotrophins on treatment outcome has been explored in the long GnRH agonist protocol in several randomised controlled trials (RCTs) and recent meta-analyses demonstrate the use of menotrophins for controlled ovarian stimulation provide higher ongoing pregnancy / live birth rates than rFSH.

This presentation will include data comparing the efficacy and safety of HP-hMG (MENOPUR) and rFSH in a large randomised controlled trial that incorporates new trends in clinical practice including GnRH antagonist down-regulation, lower starting gonadotrophins doses, compulsory single embryo transfer at the blastocyst stage for all patients in the fresh cycle as well as in the subsequent frozen embryo replacement (vitrified blastocysts) in natural cycles (Nyboe Andersen et al. 2011).